Cullgen is a San Diego-based biotechnology company developing small molecule therapeutics based on its proprietary targeted protein degradation (“TPD”) technology, uSMITE(TM). The company’s technology is a type of precision medicine that has the potential to address a broad range of intracellular disease targets, such as oncology, inflammation, CNS, and other diseases that cannot be addressed by existing therapies, commonly referred to as “undruggable” targets. Cullgen is currently developing a number of TPD-based therapeutics in-house, primarily for oncology, that are available for co-development or licensure. The company now has an IND pending for its most advanced candidate, CG001419, a TRK protein degrader for cancer and other disease applications. In addition to its internal pipeline of TPD programs, Cullgen is also discovering and developing novel E3 ligands in order to enhance the overall robustness and effectiveness of TPD therapeutics. The company believes that the development of novel E3 ligands will be one of the key long-term success factors for this technology. Through the use of novel E3 ligands, Cullgen will be able to design TPDs that are capable of recruiting and binding to one of the hundreds of existing E3 ligases that have never been utilized as part of a TPD therapeutic. Designing a TPD that has the capability to bind to a specific E3 ligase that is essential, ubiquitously expressed, or expressed in very low amounts in a given tissue will allow Cullgen to develop degraders with reduced toxicity, enhanced tissue selectivity, and the ability to overcome drug resistance. Thus far, the company has found several novel E3 ligands that meet such needs and have demonstrated that, in certain situations, they are superior to the use of VHL or CRBN. For more information, visit the company’s website at www.Cullgen.com.
To schedule a one-on-one meeting, please contact your Roth representative.
To view IBN’s virtual coverage of Roth’s 34th Annual Conference, visit https://ibn.fm/Roth2022
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at Roth’s 34th Annual Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]